C3.ai, Inc. announced that Genentech has selected C3 AI Reliability as the continued provider for AI-based predictive maintenance software on the company's biologics manufacturing equipment. The biotechnology company began using the AI application in 2021 to ensure centrifuges in the facility remained operational, with patients ultimately benefiting by receiving their medicines on time. Genentech uses this facility to manufacture biologics, a specific class of medicine that is extremely complex, time consuming, and resource intensive to develop and deliver to patients.

These medicines help patients with some of the most difficult to treat diseases, from multiple sclerosis and macular degeneration to blood cancers such as lymphoma and leukemia. In 2022, Genentech expanded its use of C3 AI Reliability to new assets beyond centrifuges -- scaling its AI footprint to around 200 pieces of equipment total. In addition to increasing the number of assets, the company also broadened employee training for the C3 AI Platform, on which the predictive maintenance application runs.

The biotechnology company now has nearly 200 users -- from data scientists to facility managers -- who are trained on the C3 AI Platform and regularly use the AI application to evaluate equipment health and maintain manufacturing operations.